VALUE-MG update

VALUE-MG

An Australian national research study for optimising the use of IVIg therapy in people with Myasthenia Gravis (MG)

VALUE-MG is a health-economic study examining the cost-effectiveness of intravenous immunoglobulin (IVIg) therapy in Australians with MG. We are pleased to announce that the recruitment stage for the VALUE-MG study has now been completed. The multi-site study coordinator, Dr. Yifat Biran, has reported that 215 participants have been recruited over a 20-months period from 5 MGBase centers across Australia. Exceeding the target number of participants was achieved by the effective collaboration between Monash University researches, clinicians, consumers, MGBase and other stakeholders.

The study is now in the follow-up stage until March 2027, during which participants will continue to complete quarterly online Quality of Life (QoL) surveys. Responses will be linked with clinical information from MGBase registry, as well as healthcare use and costs data from hospital and government datasets. We look forward to updating you on the progress of the study and its results.